Project Grant R41HL170874
Award Date
8/24/23
Completion Date
7/31/24
Dollars Obligated
$278K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Portland, OR 97239, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $391,250.00 to Emory University to investigate fibrinogen as a potential mediator of COVID-19-associated coagulopathy. The research aims to define the impact of therapeutic plasma exchange on blood rheology and vascular integrity in COVID-19 patients, as well as the role of a specific fibrinogen isoform in altering blood...
This Project Grant award of $151,523 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of fibrinogen in regulating thromboinflammation in acute and chronic venous thrombosis. The principal investigator will use novel RNA therapy, delivered via lipid nanoparticles, to selectively reduce circulating fibrinogen levels in rodent and swine models of thrombosis. The goal is to provide...
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) awarded a $503,637 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Kentucky Research Foundation. The 4-year grant, spanning January 2025 to November 2028, will fund research to investigate the mechanisms leading to thrombotic events and microclot formation in patients with COVID-19, both during acute infection and post-infection. The study aims to...
This National Heart, Lung, and Blood Institute (NHLBI) Project Grant award for $300,000, with a performance period from September 10, 2024 to September 9, 2025, supports research by Gigamune, Inc. to develop an in vivo gene therapy for sickle cell disease using a novel lentiviral vector technology. The project aims to assess the efficiency and specificity of the company's "GigaLenti" lentiviral vector platform in delivering CRISPR/Cas9 gene editing machinery to knockout the BCL11A...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), will fund research to develop a non-viral gene editing approach to treat familial hypercholesterolemia (FH). The $1,716,429.77 award will support studies to compare the efficiency and specificity of using lipid nanoparticles (LNPs), electroporation, and adeno-associated viruses (AAVs) to deliver CRISPR-Cas9 gene editing components...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant under CFDA 93.837 (Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test that can rapidly measure anti-Factor Xa activity and hemoglobin levels. This device is intended to guide emergency management of patients on direct oral anticoagulants, enabling quicker delivery of life-saving interventions during bleeding events or strokes. The project will...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the development of a platform technology to measure the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This new platform will enable the optimization of treatment discovery, patient response...
This federal Project Grant award of $471,364 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the roles of synthetic glycosaminoglycan mimetics in regulating megakaryopoiesis and thrombopoiesis. The project, led by a K12 postdoctoral scholar at the University of North Texas, aims to determine the nature of interaction between a specific glycosaminoglycan mimetic compound (G4.1) and the...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $445,500 Project Grant under the Cardiovascular Diseases Research Program (CFDA 93.837) to Cleveland State University (CSU) for the project "Chemoenzymatic Semisynthesis of Proteoglycan and Its Cofactor Activities". The project aims to synthesize recombinant thrombomodulin (TM) conjugates with chondroitin sulfate glycosaminoglycan (CSGAG) and liposomes to investigate the roles of CSGAG and lipids in the activation of...